牙龈卟啉单胞菌在非酒精性脂肪肝病进展中的作用

doi:10.13591/j.cnki.kqyx.2024.02.014

Abstract

Abstract:

Porphyromonas gingivalis(P. gingivalis), a key pathogen of periodontitis, not only harms oral health, but also has an important relationship with the development of many extraoral diseases, such as non-alcoholic fatty liver disease. P. gingivalis and its products can promote the development of non-alcoholic fatty liver disease through hematogenous and intestinal pathways. In this paper, the pathway and possible internal mechanisms involved are briefly described.

Key words: Porphyromonas gingivalis, periodontitis, non-alcoholic fatty liver disease, hematogenous pathway, intestinal pathway

CLC Number:

R781.4

DAI Ke, DAI Zhouli, LIU Rongchang, ZHA Guangyu, CAO Mingguo. The role of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease[J]. Stomatology, 2024, 44(2): 152-155.

References 43

[1]	Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD:A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1):60-78.
[2]	Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH:Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1):11-20. doi: 10.1038/nrgastro.2017.109 pmid: 28930295
[3]	Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J]. Hepatology, 2016, 64(5):1577-1586. doi: 10.1002/hep.28785 pmid: 27543837
[4]	Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012
[5]	Weintraub JA, Lopez Mitnik G, Dye BA. Oral diseases associated with nonalcoholic fatty liver disease in the United States[J]. J Dent Res, 2019, 98(11):1219-1226. doi: 10.1177/0022034519866442 pmid: 31369716
[6]	Akinkugbe AA, Slade GD, Barritt AS, et al. Periodontitis and non-alcoholic fatty liver disease, a population-based cohort investigation in the study of health in pomerania[J]. J Clin Periodontol, 2017, 44(11):1077-1087. doi: 10.1111/jcpe.12800 pmid: 28804947
[7]	Kwon T, Lamster IB, Levin L. Current concepts in the manage-ment of periodontitis[J]. Int Dent J, 2021, 71(6):462-476. doi: 10.1111/idj.12630
[8]	Kim S, Bando Y, Chang C, et al. Topical application of Porphyromonas gingivalis into the gingival pocket in mice leads to chronic-active infection, periodontitis and systemic inflammation[J]. Int J Mol Med, 2022, 50(2):103. doi: 10.3892/ijmm
[9]	Ryder MI. Porphyromonas gingivalis and Alzheimer disease:Recent findings and potential therapies[J]. J Periodontol, 2020, 91(Suppl 1):S45-S49.
[10]	Xie MR, Tang QM, Nie JM, et al. BMAL1-downregulation aggravates Porphyromonas gingivalis-induced atherosclerosis by encouraging oxidative stress[J]. Circ Res, 2020, 126(6):e15-e29.
[11]	Kajiwara K, Sawa Y. Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model[J]. BMC Nephrol, 2021, 22(1):287. doi: 10.1186/s12882-021-02506-8
[12]	Omura Y, Kitamoto M, Hyogo H, et al. Morbidly obese patient with non-alcoholic steatohepatitis-related cirrhosis who died from Sepsis caused by dental infection of Porphyromonas gingivalis: A case report[J]. Hepatol Res, 2016, 46(3):E210-E215.
[13]	Alakhali MS, Al-Maweri SA, Al-Shamiri HM, et al. The potential association between periodontitis and non-alcoholic fatty liver disease:A systematic review[J]. Clin Oral Investig, 2018, 22(9):2965-2974. doi: 10.1007/s00784-018-2726-1
[14]	Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism[J]. Sci Rep, 2017, 7(1):13950. doi: 10.1038/s41598-017-14260-9 pmid: 29066788
[15]	Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases[J]. J Periodontol, 2013, 84(4 Suppl):S51-S69.
[16]	Fujita M, Kuraji R, Ito H, et al. Histological effects and pharmacokinetics of lipopolysaccharide derived from Porphyromonas gingivalis on rat maxilla and liver concerning with progression into non-alcoholic steatohepatitis[J]. J Periodontol, 2018, 89(9):1101-1111. doi: 10.1002/jper.2018.89.issue-9
[17]	Nagasaki A, Sakamoto S, Chea C, et al. Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation[J]. Sci Rep, 2020, 10:4134. doi: 10.1038/s41598-020-60904-8
[18]	Furusho H, Miyauchi M, Hyogo H, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice[J]. J Gastroenterol, 2013, 48(11):1259-1270. doi: 10.1007/s00535-012-0738-1 pmid: 23307045
[19]	Varela-López A, Bullón P, Ramírez-Tortosa CL, et al. A diet rich in saturated fat and cholesterol aggravates the effect of bacterial lipopolysaccharide on alveolar bone loss in a rabbit model of periodontal disease[J]. Nutrients, 2020, 12(5):1405. doi: 10.3390/nu12051405
[20]	Sasaki N, Katagiri S, Komazaki R, et al. Endotoxemia by Porphyromonas gingivalis injection aggravates non-alcoholic fatty liver disease, disrupts glucose/lipid metabolism, and alters gut microbiota in mice[J]. Front Microbiol, 2018, 9:2470. doi: 10.3389/fmicb.2018.02470 pmid: 30405551
[21]	Ding LY, Liang LZ, Zhao YX, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways[J]. Oral Dis, 2019, 25(7):1789-1797. doi: 10.1111/odi.v25.7
[22]	Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease[J]. J Gastroenterol, 2018, 53(2):269-280. doi: 10.1007/s00535-017-1368-4 pmid: 28741270
[23]	Wada K, Kamisaki Y. Roles of oral bacteria in cardiovascular diseases:From molecular mechanisms to clinical cases:Involvement of Porphyromonas gingivalis in the development of human aortic aneurysm[J]. J Pharmacol Sci, 2010, 113(2):115-119. doi: 10.1254/jphs.09R22FM
[24]	Tian J, Liu C, Zheng X, et al. Porphyromonas gingivalis induces insulin resistance by increasing BCAA levels in mice[J]. J Dent Res, 2020, 99(7):839-846. doi: 10.1177/0022034520911037 pmid: 32176550
[25]	Wu L, Shi R, Bai HM, et al. Porphyromonas gingivalis induces increases in branched-chain amino acid levels and exacerbates liver injury through livh/livk[J]. Front Cell Infect Microbiol, 2022, 12:776996. doi: 10.3389/fcimb.2022.776996
[26]	Nagasaki A, Sakamoto S, Arai T, et al. Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH[J]. J Clin Periodontol, 2021, 48(10):1367-1378. doi: 10.1111/jcpe.v48.10
[27]	Saygun I, Nizam N, Keskiner I, et al. Salivary infectious agents and periodontal disease status[J]. J Periodontal Res, 2011, 46(2):235-239. doi: 10.1111/j.1600-0765.2010.01335.x pmid: 21261620
[28]	Yoneda M, Naka SH, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2012, 12:16. doi: 10.1186/1471-230X-12-16
[29]	Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota[J]. Sci Rep, 2014, 4:4828. doi: 10.1038/srep04828 pmid: 24797416
[30]	Nakajima M, Arimatsu K, Kato T, et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver[J]. PLoS One, 2015, 10(7):e0134234. doi: 10.1371/journal.pone.0134234
[31]	Yamazaki K, Kato T, Tsuboi Y, et al. Oral pathobiont-induced changes in gut microbiota aggravate the pathology of nonalcoholic fatty liver disease in mice[J]. Front Immunol, 2021, 12:766170. doi: 10.3389/fimmu.2021.766170
[32]	Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice[J]. FASEB J, 2008, 22(7):2416-2426. doi: 10.1096/fj.07-102723 pmid: 18326786
[33]	Vallianou N, Christodoulatos GS, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease:Current evidence and perspectives[J]. Biomolecules, 2021, 12(1):56. doi: 10.3390/biom12010056
[34]	Kato T, Yamazaki K, Nakajima M, et al. Oral administration of Porphyromonas gingivalis alters the gut microbiome and serum metabolome[J]. mSphere, 2018, 3(5):e00460-e00418.
[35]	Zhang ST, Li X, Luo HH, et al. Role of aromatic amino acids in pathogeneses of diabetic nephropathy in Chinese patients with type 2 diabetes[J]. J Diabetes Complications, 2020, 34(10):107667. doi: 10.1016/j.jdiacomp.2020.107667
[36]	Liu RX, Hong J, Xu XQ, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention[J]. Nat Med, 2017, 23(7):859-868. doi: 10.1038/nm.4358 pmid: 28628112
[37]	Du K, Chitneni SK, Suzuki A, et al. Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression[J]. Cell Mol Gastroenterol Hepatol, 2020, 10(1):1-21. doi: S2352-345X(19)30182-1 pmid: 31881361
[38]	Alshawsh MA, Alsalahi A, Alshehade SA, et al. A comparison of the gene expression profiles of non-alcoholic fatty liver disease between animal models of a high-fat diet and methionine-choline-deficient diet[J]. Molecules, 2022, 27(3):858. doi: 10.3390/molecules27030858
[39]	Kini V, Mohanty I, Telang G, et al. Immunopathogenesis and distinct role of Th17 in periodontitis:A review[J]. J Oral Biosci, 2022, 64(2):193-201. doi: 10.1016/j.job.2022.04.005
[40]	Wang LY, Wang JY, Jin Y, et al. Oral administration of all-trans retinoic acid suppresses experimental periodontitis by modulating the Th17/Treg imbalance[J]. J Periodontol, 2014, 85(5):740-750. doi: 10.1902/jop.2013.130132 pmid: 23952076
[41]	Kitamoto S, Nagao-Kitamoto H, Jiao YZ, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis[J]. Cell, 2020, 182(2):447-462.e14. doi: S0092-8674(20)30681-4 pmid: 32758418
[42]	Hatasa M, Yoshida S, Takahashi H, et al. Relationship between NAFLD and periodontal disease from the view of clinical and basic research, and immunological response[J]. Int J Mol Sci, 2021, 22(7):3728. doi: 10.3390/ijms22073728
[43]	Tomofuji T, Ekuni D, Sanbe T, et al. Effects of improvement in periodontal inflammation by toothbrushing on serum lipopolysaccharide concentration and liver injury in rats[J]. Acta Odontol Scand, 2009, 67(4):200-205. doi: 10.1080/00016350902794818 pmid: 19301160

The role of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 43

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	REN Jiayu, REN Xiuyun. Research progress of oxidative stress and antioxidant adjuvant therapy for periodontitis [J]. Stomatology, 2024, 44(2): 148-151.
[2]	ZHAO Mingyu, SHI Binmian, XIE Xudong, XU Chunmei, WANG Jun. Research progress of luteolin in the prevention and treatment for periodontitis [J]. Stomatology, 2024, 44(2): 126-129.
[3]	TANG Lu, XUE Dong, YANG Wenwen, ZHANG Xianli, LU Xia, ZHAO Ying. Distribution of periodontal pathogens in carotid atherosclerotic plaques with different degrees of carotid artery stenosis [J]. Stomatology, 2024, 44(1): 31-35.
[4]	TANG Jinxin, TANG Chunbo, SONG Xin, RUI Na, XUE Chang'ao. Establishment of risk prediction model for peri-implantitis after dental implants in patients with periodontitis [J]. Stomatology, 2023, 43(8): 706-710.
[5]	ZHANG Min, MEI Youmin, YUAN Jianfen, SUN Jingwei, XU Jiali, YAN Junyi, LI Qiao, ZHOU Yan, SHEN Xiang. Correlation analysis between Helicobacter pylori infection and periodontitis in 127 cases [J]. Stomatology, 2023, 43(8): 702-705.
[6]	CAI Bobo, SI Misi. Research progress of immediate implant placement with fixed full-arch prosthesis in patients with severe periodontitis [J]. Stomatology, 2023, 43(7): 663-666.
[7]	LI Shaohua, LIN Xiaoping. Research progress of the relationship between periodontitis and non-alcoholic fatty liver disease [J]. Stomatology, 2023, 43(7): 652-656.
[8]	JIANG Lishan, YANG Zhiyu, SHI Jiahong, WANG Jinmeng, LEI Lang, LI Houxuan. Therapeutic effect and influencing factors of hopeless teeth with Stage Ⅳ Grade C periodontitis: A retrospective study [J]. Stomatology, 2023, 43(7): 633-637.
[9]	ZHANG Yifei, YANG Qi, LI Cheng, LI Lu. Clinical application of Nd:YAG laser to improve the periodontal microecological imbalance in periodontitis patients with type 2 diabetes mellitus [J]. Stomatology, 2023, 43(7): 619-624.
[10]	FENG Zehua, QIU Shuang, XU Xuanwen, ZHENG Kai, XU Yan. In vitro anti-inflammatory effects of mesoporous bioactive glasses/polycaprolactone fibrous bone tissue engineering scaffolds [J]. Stomatology, 2023, 43(7): 592-599.
[11]	TIAN Shilin, CHEN Xiaotao. Research progress of oxidative stress level and iron metabolism in periodontitis [J]. Stomatology, 2023, 43(6): 552-555.
[12]	ZHOU Huirong, LIN Xiaoping. Research advances in correlation between chronic periodontitis and prostatic diseases [J]. Stomatology, 2023, 43(3): 273-277.
[13]	WANG Dexu, LUO Xiaojie, CHEN Xiaotao. Research progress of research on the effect of quorum-sensing system on periodontal pathogens [J]. Stomatology, 2023, 43(3): 267-272.
[14]	XIE Yongmei, GE Huabing, FENG Jie, LIU Qi, ZHANG Ning, ZHONG Xiaoli. A short-term efficacy evaluation of biological antibacterial peptides in the adjuvant therapy of stageⅢ periodontitis [J]. Stomatology, 2023, 43(3): 237-241.
[15]	ZHANG Chaoying, GONG Jiaxing, YU Mengfei, QIAN Ying, ZHU Ziyu, LU Kejie, WANG Huiming. Application progress of alveolar ridge preservation in patients with tooth extracted due to periodontitis [J]. Stomatology, 2023, 43(2): 159-165.